1. Home
  2. WING vs CRNX Comparison

WING vs CRNX Comparison

Compare WING & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wingstop Inc.

WING

Wingstop Inc.

HOLD

Current Price

$116.82

Market Cap

4.4B

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$84.08

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WING
CRNX
Founded
1994
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
3.9B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
WING
CRNX
Price
$116.82
$84.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
27
8
Target Price
$295.92
$76.75
AVG Volume (30 Days)
1.3M
3.8M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
0.70%
N/A
EPS Growth
67.84
N/A
EPS
2.23
N/A
Revenue
$696,853,000.00
$1,039,000.00
Revenue This Year
$17.20
$720.10
Revenue Next Year
$15.86
$184.67
P/E Ratio
$52.30
N/A
Revenue Growth
11.35
N/A
52 Week Low
$116.25
$26.50
52 Week High
$345.81
$84.09

Technical Indicators

Market Signals
Indicator
WING
CRNX
Relative Strength Index (RSI) 28.87 89.87
Support Level $116.35 $43.40
Resistance Level $176.24 $84.00
Average True Range (ATR) 8.67 0.21
MACD -1.79 -1.71
Stochastic Oscillator 1.08 73.17

Price Performance

Historical Comparison
WING
CRNX

About WING Wingstop Inc.

Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: